The US Bankruptcy Court approved the combined hearing to consider approval of disclosure statement and plan on Interim basis of PhaseBio Pharmaceuticals, Inc. on August 1, 2023. The debtor had filed its combined disclosure statement and plan in the Court on August 1, 2023. The voting record date is July 31, 2023.

The deadline to vote on the plan is September 6, 2023. Any objections to the plan should be made before September 6, 2023, and the confirmation hearing for the plan and disclosure statement has been scheduled for September 19, 2023.